Your Trusted Brand for Over 35 Years

Daily News

Recent Findings in Prostate Cancer Described by Researchers from University Health Network


By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on Prostate Cancer. According to news originating from Toronto, Canada, by NewsRx correspondents, research stated, "MiR-100 and miR-125b are lost in many cancers and have potential function as tumor suppressors. Using both primary prostatic epithelial cultures and laser capture-microdissected prostate epithelium from 45 patients enrolled in a vitamin D-3 randomized trial, we identified miR-100 and -125b as targets of 1,25-dihydroxyvitamin D-3 (1,25D)."

Our news journalists obtained a quote from the research from University Health Network, "In patients, miR-100 and -125b levels were significantly lower in tumor tissue than in benign prostate. Similarly, miR-100 and -125b were lower in primary prostate cancer cells than in cells derived from benign prostate. Prostatic concentrations of 1,25D positively correlated with these miRNA levels in both prostate cancer and benign epithelium, showing that patients with prostate cancer may still benefit from vitamin D-3. In cell assays, upregulation of these miRNAs by 1,25D was vitamin D receptor dependent. Transfection of pre-miR-100 and pre-miR-125b in the presence or absence of 1,25D decreased invasiveness of cancer cell, RWPE-2. Pre-miR-100 and pre-miR-125b decreased proliferation in primary cells and cancer cells respectively. Pre-miR-125b transfection suppressed migration and clonal growth of prostate cancer cells, whereas knockdown of miR-125b in normal cells increased migration indicates a tumor suppressor function. 1,25D suppressed expression of previously bona fide mRNA targets of these miRNAs, E2F3 and Plk1, in a miRNA-dependent manner."

According to the news editors, the research concluded: "Together, these findings show that vitamin D-3 supplementation augments tumor suppressive miRNAs in patient prostate tissue, providing evidence that miRNAs could be key physiologic mediators of vitamin D-3 activity in prevention and early treatment of prostate cancer."

For more information on this research see: Tumor Suppressor microRNAs, miR-100 and-125b, Are Regulated by 1,25-dihydroxyvitamin D in Primary Prostate Cells and in Patient Tissue. Cancer Prevention Research, 2013;6(5):483-494. Cancer Prevention Research can be contacted at: Amer Assoc Cancer Research, 615 Chestnut St, 17TH Floor, Philadelphia, PA 19106-4404, USA. (American Association for Cancer Research -; Cancer Prevention Research -

The news correspondents report that additional information may be obtained from A.A. Giangreco, Univ Hlth Network, Dept. of Pathol, Toronto, ON, Canada (see also Prostate Cancer).

Keywords for this news article include: Canada, Toronto, Ontario, Oncology, Prostate Cancer, Tumor Suppression, Prostatic Neoplasms, North and Central America, Clinical Trials and Studies

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC

To see more of the, or to subscribe, go to .

Articles featured in Life Extension Daily News are derived from a variety of news sources and are provided as a service by Life Extension. These articles, while of potential interest to readers of Life Extension Daily News, do not necessarily represent the opinions nor constitute the advice of Life Extension.